Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
作者信息
Olisova Olga Yu, Anpilogova Ekaterina M, Svistunova Dariya A
机构信息
Dermatology Department, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
出版信息
Dermatol Ther. 2020 Jul;33(4):e13668. doi: 10.1111/dth.13668. Epub 2020 Jun 24.
Abstract
摘要
相似文献
1
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.阿普司特作为治疗新冠肺炎的潜在选择：一名银屑病患者无感染症状。
Dermatol Ther. 2020 Jul;33(4):e13668. doi: 10.1111/dth.13668. Epub 2020 Jun 24.
2
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.患有少突胶质细胞瘤的红皮病型银屑病患者的COVID-19肺部感染：阿普米司特与重症监护管理的安全性和兼容性
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
3
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.银屑病患者的机会性病毒感染：在新冠疫情时代阿普米拉斯更安全的选择。
Dermatol Ther. 2020 Jul;33(4):e13618. doi: 10.1111/dth.13618. Epub 2020 Jun 4.
4
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.在加拿大两家学术医院诊所和一家社区诊所的COVID-19大流行期间，患者驱动的阿普斯特停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):418-419. doi: 10.1177/1203475420928382. Epub 2020 May 12.
5
Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.银屑病和银屑病关节炎：在新冠疫情期间如何管理免疫抑制剂
Dermatol Ther. 2020 Jul;33(4):e13415. doi: 10.1111/dth.13415. Epub 2020 May 2.
6
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.一名患有银屑病和银屑病关节炎的患者在使用阿达木单抗治疗期间COVID-19感染的非复杂病程。
Dermatol Ther. 2020 Jul;33(4):e13708. doi: 10.1111/dth.13708. Epub 2020 Jun 26.
7
Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".回复：“2019冠状病毒病、梅毒与银屑病和银屑病关节炎的生物疗法：一则警示”
J Am Acad Dermatol. 2020 Jun;82(6):e215. doi: 10.1016/j.jaad.2020.03.103. Epub 2020 Apr 10.
8
COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.新型冠状病毒肺炎、梅毒与银屑病及银屑病关节炎的生物治疗：一则警示
J Am Acad Dermatol. 2020 Jun;82(6):e213. doi: 10.1016/j.jaad.2020.03.079. Epub 2020 Apr 1.
9
COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.新冠疫情时代：一个了解生物治疗中银屑病患者监测新情况的机会。
Dermatol Ther. 2020 Jul;33(4):e13805. doi: 10.1111/dth.13805. Epub 2020 Jul 13.
10
Use of Apremilast in Patients With Psoriatic Arthritis During the COVID-19 Pandemic: Comment on the Article by Mikuls et al.在新冠疫情期间阿普米司特在银屑病关节炎患者中的应用：对米库尔斯等人文章的评论
Arthritis Rheumatol. 2021 Mar;73(3):547-548. doi: 10.1002/art.41575. Epub 2021 Jan 29.
引用本文的文献
1
Dermatology Publications on COVID-19 during the First Pandemic Year: Creativity or Opportunism?大流行第一年关于新冠病毒的皮肤病学出版物：是创新还是投机？
Life (Basel). 2023 Apr 5;13(4):953. doi: 10.3390/life13040953.
2
Apremilast in Psoriasis Patients With Serious Comorbidities: a Case Series and Systematic Review of Literature.阿普司特治疗伴有严重合并症的银屑病患者：病例系列及文献系统评价
Dermatol Pract Concept. 2022 Oct 1;12(4):e2022179. doi: 10.5826/dpc.1204a179. eCollection 2022 Nov.
3
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.银屑病患者接受白细胞介素-17 抑制剂治疗后感染 COVID-19、住院和死亡的风险：系统评价和荟萃分析。
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
4
Apremilast in Paediatric Dermatoses - A Comprehensive Review.阿普米司特治疗儿童皮肤病——全面综述
Indian J Dermatol. 2022 Mar-Apr;67(2):206. doi: 10.4103/ijd.ijd_482_21.
5
COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis.脊柱关节炎患者的 COVID-19 结局与疫苗接种
Rheumatol Ther. 2022 Aug;9(4):993-1016. doi: 10.1007/s40744-022-00462-9. Epub 2022 May 22.
6
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.2019年冠状病毒病大流行期间中重度银屑病的治疗：经验教训与机遇
J Clin Med. 2022 Apr 26;11(9):2422. doi: 10.3390/jcm11092422.
7
Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis.阿普司特可改善银屑病患者的内皮糖萼完整性、血管及左心室心肌功能。
Pharmaceuticals (Basel). 2022 Jan 30;15(2):172. doi: 10.3390/ph15020172.
8
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.2019年冠状病毒病大流行期间银屑病的管理
J Clin Aesthet Dermatol. 2021 Sep;14(9):41-44.
9
Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.使用阿普斯特治疗的银屑病患者中新冠病毒疾病的发病率和预后：一项多中心回顾性队列研究
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e94-e95. doi: 10.1111/jdv.17749. Epub 2021 Oct 28.
10
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.基于多组学的 SARS-CoV-2 感染生物学鉴定和抗 COVID-19 的候选药物。
Comput Biol Med. 2020 Nov;126:104051. doi: 10.1016/j.compbiomed.2020.104051. Epub 2020 Oct 10.
本文引用的文献
1
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.患有少突胶质细胞瘤的红皮病型银屑病患者的COVID-19肺部感染：阿普米司特与重症监护管理的安全性和兼容性
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
2
Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.一名银屑病患者注射古塞库单抗后新冠病毒症状改善。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e363-e364. doi: 10.1111/jdv.16590. Epub 2020 Jun 4.
3
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.4例接受生物制剂治疗的银屑病患者的新型冠状病毒肺炎感染演变情况
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
4
SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.一名接受白细胞介素-17抑制剂治疗的银屑病患者感染了新型冠状病毒。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e357-e358. doi: 10.1111/jdv.16571. Epub 2020 Jun 8.
5
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.管理 COVID-19 大流行期间的皮肤免疫介导性疾病。
Am J Clin Dermatol. 2020 Jun;21(3):307-311. doi: 10.1007/s40257-020-00514-2.
6
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
7
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.新型冠状病毒肺炎与银屑病：是时候限制免疫抑制剂的使用了吗？呼吁采取行动。
Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.
Zotero 插件